GUI Huitong Pharmaceutical Group once again made a breakthrough on the basis of hybrid second generation Maoci mushroom, and successfully developed the best variety of Maoci mushroom [Bing Bai 1].

The research laboratory of Guangxi Guihuitong Pharmaceutical Group Co., Ltd. has successfully developed the hybrid second-generation seedling of "Bingbai No. 1", which marks a major breakthrough in the artificial cultivation technology of hairy mushroom. 【 Bingbai 1 】 Through modern biotechnology means, wild hairy mushroom hybridization and improvement, gene editing splicing, 【 Bingbai 1 】 has the following advantages:

Excellent quality: the content of effective ingredients is significantly increased, the content of colchicine is more than 16 times that of ordinary, and the medicinal value is significantly higher.

Strong stress resistance: enhanced resistance to pests and environmental stress, wider adaptability, can adapt to the low temperature of minus 25 degrees.

Stable output: the growth cycle is shortened, 1 year can be harvested, and the output is greatly increased to meet the market demand.

【 Bingbai No. 1 】 is currently the best and most suitable variety for the promotion and planting of Maoci mushroom, which can be planted in both north and south. The launch of 【 Bingbai No. 1 】 will effectively relieve the pressure on wild Maoci mushroom resources, promote the sustainable development of Chinese medicinal materials industry, and contribute to the modernization of Chinese medicine.